Castle Biosciences (CSTL) Change in Accured Expenses (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Change in Accured Expenses data on file, last reported at $2.8 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 141.45% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (up 57.03% YoY) and the FY2025 annual result came in at $5.7 million, up 58.78% from the prior year.
• Change in Accured Expenses slipped to $2.8 million in Q1 2026 per CSTL's latest filing, from $3.8 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $8.4 million in Q3 2023, with the low at -$11.6 million in Q1 2023.
• Average Change in Accured Expenses over 5 years is $924764.7, with a median of $160000.0 recorded in 2022.
• The widest YoY moves for Change in Accured Expenses: up 5172.5% in 2023, down 39968.97% in 2023.
• Castle Biosciences' Change in Accured Expenses stood at -$110000.0 in 2022, then jumped by 3019.09% to $3.2 million in 2023, then surged by 52.07% to $4.9 million in 2024, then declined by 21.56% to $3.8 million in 2025, then fell by 28.07% to $2.8 million in 2026.
• Business Quant data shows CSTL's Change in Accured Expenses at $2.8 million in Q1 2026, $3.8 million in Q4 2025, and $1.4 million in Q3 2025.